THAR vs AMTD Comparison

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.